World of DTC Marketing
AUGUST 12, 2022
PhRMA is lying to protect its profits, and the lies have reached a new height as the Senate moved to adopt modest drug pricing negotiation measures in the Inflation Reduction Act. The bill “could propel us light-years back into the dark ages of biomedical research,” Dr. Michelle McMurry-Heath, president of the Biotechnology Innovation Organization, said last month.
pharmaphorum
AUGUST 8, 2022
A study of a mobile health app used to support patients hospitalised with heart failure has concluded that it provided a modest improvement in quality-of-life scores, as well as better clinical outcomes. The finding comes from the large-scale CONNECT-HF cluster study, which looked at various patient engagement and education interventions to see if they could help patients with heart failure do better after discharge from hospital.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
AUGUST 12, 2022
In June this year, it was announced that the US Food and Drug Administration (FDA) had granted UK-based OxfordVR a breakthrough device designation for its gameChangeVR treatment to deliver immersive cognitive behaviour therapy (CBT) to people suffering from schizophrenia and other mental illnesses. The FDA’s breakthrough device programme is for medical devices or device-led combination products that provide more effective treatment or diagnosis of diseases.
MedCity News
AUGUST 7, 2022
Nonhuman primates will be critical to our efforts to understand the long-term effects of Covid-19. Yet scientists conducting critical research have faced harassment and threats.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
World of DTC Marketing
AUGUST 10, 2022
CPG marketers are trying to maintain market share amid price increases and smaller product sizes, leading to a more significant jump in consumerism. But, in pharma marketing, the changes affect every product category. Consumers share more information online than ever as inflation cuts into their disposable income. I’ve seen posts on everything from opinions on detergents to the best and more inexpensive ice cream.
PharmExec
AUGUST 10, 2022
Curative-type therapies offer great hope in further transforming treatments for cancer and other diseases, but addressing the economics of these products—and ultimately the cost-benefit equation—is daunting. What is being done to smooth the path for pricing and reimbursement?
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
MedCity News
AUGUST 8, 2022
An expert industry observer said CVS Health’s move into primary care is both offensive and defensive, but perhaps more importantly a natural evolution of a company with such a large healthcare footprint.
World of DTC Marketing
AUGUST 8, 2022
Consumers have changed their shopping behavior due to the pandemic, and some of those changes are relevant for pharma marketers. The days of someone seeing an ad for a prescription drug and rushing to ask their doctor about it have replaced the quest for more information, usually online. CPG brands have finally admitted that consumers are changing how they purchase products and brands.
PharmExec
AUGUST 10, 2022
Marie-France Tschudin, president, innovative medicines international, and chief commercial officer at Novartis, taps into life lessons to help bring therapies to people in novel ways.
PharmaVoice
AUGUST 10, 2022
Miruna Sasu is on a mission to use real world data to help wipe out cancer. She believes this audacious goal is within reach, and as president and CEO of COTA, she is inspiring her team to create a “path to care” for oncology patients.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
MedCity News
AUGUST 10, 2022
UNC Health recently partnered with Gozio Health and WELL Health to add new features to its app. Patients can now download the app via a link sent in appointment reminder texts, view a map of immediate care options near them and access appointment wayfinding via their mobile phone calendar.
Copyright Clearance Center
AUGUST 9, 2022
August 9, 20 22 – Danvers, Mass. – CCC , a leader in advancing copyright, accelerating knowledge, and powering innovation, is now offering subscriptions to select publishers including the JAMA Network and the New England Journal of Medicine (NEJM) through CCC’s advanced content workflow solution, RightFind , to meet the needs of researchers in organizations with fewer than 500 employees.
Medgadget
AUGUST 11, 2022
Engineers at MIT have created an ultrasound patch that can provide long-term ultrasound imaging of internal organs and structures. The device contains a rigid piezoelectric probe array and uses an underlying layer of elastomer-covered hydrogel in lieu of the gel applied to the skin during conventional ultrasound procedures. At just the size of a postage stamp, the ultrasound patch is highly portable and less expensive than conventional ultrasound technologies.
pharmaphorum
AUGUST 8, 2022
Pfizer’s reported interest in acquiring sickle cell disease specialist Global Blood Therapeutics (GBT) has been confirmed, with the $68.50-per-share deal valuing GBT at $5.4 billion. As we reported this morning, the deal gives Pfizer already-approved SCD therapy Oxbryta (voxelator) – which industry watchers reckon could see a dramatic uptick in sales with Pfizer’s marketing muscle – plus a phase 3 antibody candidate, a phase 1 follow-up to Oxbryta that could offer improved dosing.
Advertiser: ZoomInfo
Marketing technology is essential for B2B marketers to stay competitive in a rapidly changing digital landscape — and with 53% of marketers experiencing legacy technology issues and limitations, they’re researching innovations to expand and refine their technology stacks. To help practitioners keep up with the rapidly evolving martech landscape, this special report will discuss: How practitioners are integrating technologies and systems to encourage information-sharing between departments and pr
MedCity News
AUGUST 9, 2022
Commercial insurers’ practices, such as prior authorization and white bagging, are needed to reduce costs for patients, said Kristine Grow, senior vice president of communications at AHIP.
Pharmaceutical Technology
AUGUST 12, 2022
The US Food and Drug Administration (FDA) has granted approval for Daiichi Sankyo and AstraZeneca ’s Enhertu (fam-trastuzumab deruxtecan-nxki) to treat unresectable or metastatic non-small cell lung cancer (NSCLC) in adults. The treatment is indicated for such patients whose tumours have activating HER2 (ERBB2) mutations and previously received systemic therapy. .
Medgadget
AUGUST 11, 2022
Researchers at INSERM (Institut national de la santé et de la recherche médicale) in France, and collaborators, have developed a DNA-based nanorobot called the Nano-winch. The tiny creation is made using DNA molecules and a “DNA Origami” approach. The tiny robot is so small that it can land on a cell surface and interact with ‘mechanoreceptors’ that the cell uses to sense mechanical forces acting on it.
PM360
AUGUST 9, 2022
PM360 asked life sciences industry experts with knowledge about improving adherence to medication to share the latest trends and approaches being used and to tell us how better data and monitoring can help solve this issue. Specifically, we wanted to know: What are the current biggest trends in how the life sciences industry is approaching ways to improve medication adherence?
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
MedCity News
AUGUST 7, 2022
The increases in enrollment are likely because of changes in the economy, policy changes like Medicaid expansion in the Affordable Care Act and the temporary continuous enrollment requirement from the Family First Coronavirus Response Act, the report said. .
Pharmaceutical Technology
AUGUST 8, 2022
AstraZeneca and Daiichi Sankyo ’s Enhertu (trastuzumab deruxtecan) has received expanded approval from the US Food and Drug Administration (FDA) to treat adults with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer. The treatment is indicated for patients who have previously received chemotherapy in the metastatic setting or recurred during or within six months of receiving adjuvant chemotherapy.
pharmaphorum
AUGUST 11, 2022
GSK, its consumer health spin-off Haleon and Sanofi could be on the hook for billions of dollars in potential damages over Zantac, a gastrointestinal drug pulled from the market in 2020 after it was linked to cases of cancer. That’s the conclusion of analysts at Morgan Stanley, Deutsche Bank and UBS, who have all issued research notes drawing attention to the issue, which has remained largely off the radar since sales of Zantac (ranitidine) were halted.
PM360
AUGUST 9, 2022
How can we help ensure patients continue to take their medications as prescribed? Doctors, caregivers, life sciences companies, and even companies in other industries have attempted to answer this question for as long as medications have been available. But it is not a simple answer. The reasons why a patient may not take their medication are plentiful, and as a result so are the solutions now available to attempt to solve this issue.
Advertisement
When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.
MedCity News
AUGUST 11, 2022
FundamentalVR, a startup that sells virtual reality and haptic software for medical simulation, recently closed a $20 million Series B funding round. The company will use the funds to invest in Fundamental Surgery, its platform that recreate the sights, sounds and sensations that surgeons experience during medical procedures.
Pharmaceutical Commerce
AUGUST 11, 2022
Exploring the competitive and unique offerings in three of the US’s lower-cost economic development regions—and how success in these areas has been boosted by COVID.
PharmExec
AUGUST 12, 2022
Mindy will be the creative voice of the agency, responsible for providing Greater Than One clients with strategic creative direction and oversight from inception through execution.
European Pharmaceutical Review
AUGUST 11, 2022
The Frost & Sullivan Institute stated that it is proud to present Samsung Biologics with the 2022 Enlightened Growth Leadership Award for not only demonstrating growth excellence but also social responsibility. In announcing the award, the Institute asserted that it “believes that all organisations must either create or become part of a solution that addresses threats to humanity,” highlighting Samsung’s strong environmental, social and governance (ESG) and sustainability initiatives the rea
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
MedCity News
AUGUST 7, 2022
Trinity Health Mid-Atlantic partnered with mental health software provider Neuroflow last August to mitigate healthcare’s burnout crisis by providing its nurses with the Philadelphia-based startup’s technology. A year later, the partners are saying more hospitals should roll out initiatives like this, as nurses who utilized NeuroFlow saw a quick and positive impact on their mental wellbeing.
Pharmaceutical Technology
AUGUST 12, 2022
In the lead-up to a critical meeting that will influence the approval of a new drug for amyotrophic lateral sclerosis (ALS), the US Food and Drug Administration (FDA) has detailed its plans to advance rare neurodegenerative disease research. The plan, which was released in late June, outlines a science strategy to improve research efforts for ALS. Its content is pertinent given the upcoming FDA Advisory Committee (AdCom) for Amylyx Pharmaceuticals’ ALS drug AMX0035 on 7 September.
Nixon Gwilt Law
AUGUST 10, 2022
TLDR: If you want to incentivize patient adherence to a medication adherence or substance use disorder (“ SUD ”) treatment program without running afoul of the Anti-kickback Statute (“ AKS ”) or Civil Monetary Penalties law (“ CMP ”), a recent advisory opinion indicates that evidence-based, clinically relevant incentives may be the key. Now let’s get to the details.
Scott Burrows
AUGUST 9, 2022
Resilience in Pharma Sales: Now More than Ever As a motivational sales speaker for the pharmaceutical industry, I tell my audiences that COVID-19 might also be characterized as the disease that changed an industry. It is kind of ironic.
Advertiser: ZoomInfo
In times of economic uncertainty, account-based strategies are essential. According to several business analysts and practitioners, ABM is a necessity for creating more predictable revenue. Research shows that nearly three-quarters of marketers (74%) already have the resources needed to build successful ABM programs.
Expert insights. Personalized for you.
255 
Let's personalize your content